Cantor Fitzgerald Has Negative View of BCYC FY2025 Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Analysts at Cantor Fitzgerald dropped their FY2025 earnings per share estimates for Bicycle Therapeutics in a report released on Thursday, May 8th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($3.87) for the year, down from their prior estimate of ($3.49). The consensus estimate for Bicycle Therapeutics' current full-year earnings is ($3.06) per share.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last posted its quarterly earnings data on Thursday, May 1st. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The business had revenue of $9.98 million during the quarter, compared to the consensus estimate of $8.67 million.

A number of other analysts also recently weighed in on the company. Morgan Stanley set a $17.00 target price on Bicycle Therapeutics and gave the company an "equal weight" rating in a research report on Monday, May 5th. Needham & Company LLC reissued a "buy" rating and issued a $29.00 target price on shares of Bicycle Therapeutics in a report on Friday, May 2nd. Barclays reduced their price target on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. B. Riley decreased their price objective on shares of Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating on the stock in a research note on Friday, May 2nd. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $33.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, Bicycle Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $25.00.

Bicycle Therapeutics Price Performance

NASDAQ:BCYC traded down $0.10 during trading hours on Monday, reaching $8.01. 341,746 shares of the company were exchanged, compared to its average volume of 402,244. The business has a 50 day moving average of $8.36 and a 200 day moving average of $13.53. Bicycle Therapeutics has a 1-year low of $6.10 and a 1-year high of $28.67. The company has a market capitalization of $554.72 million, a P/E ratio of -2.43 and a beta of 1.60.

Institutional Trading of Bicycle Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Point72 Asset Management L.P. lifted its stake in shares of Bicycle Therapeutics by 406.2% in the 4th quarter. Point72 Asset Management L.P. now owns 4,554,900 shares of the company's stock valued at $63,769,000 after acquiring an additional 3,655,101 shares during the last quarter. Baker BROS. Advisors LP raised its holdings in Bicycle Therapeutics by 15.8% in the 4th quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company's stock valued at $152,395,000 after buying an additional 1,485,397 shares during the last quarter. Fcpm Iii Services B.V. boosted its position in Bicycle Therapeutics by 47.5% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company's stock worth $48,333,000 after buying an additional 1,112,369 shares during the period. Long Focus Capital Management LLC bought a new stake in Bicycle Therapeutics during the 4th quarter worth approximately $7,603,000. Finally, Principal Financial Group Inc. bought a new stake in Bicycle Therapeutics during the 3rd quarter worth approximately $10,028,000. Institutional investors own 86.15% of the company's stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.